WINTON GROUP Ltd acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) in the second quarter, HoldingsChannel reports. The fund acquired 24,579 shares of the biotechnology company’s stock, valued at approximately $274,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC acquired a new stake in Corcept Therapeutics during the first quarter valued at $658,000. Tealwood Asset Management Inc. boosted its position in Corcept Therapeutics by 50.8% during the first quarter. Tealwood Asset Management Inc. now owns 154,615 shares of the biotechnology company’s stock valued at $1,815,000 after purchasing an additional 52,069 shares during the last quarter. FMR LLC boosted its position in Corcept Therapeutics by 23.3% during the fourth quarter. FMR LLC now owns 561,595 shares of the biotechnology company’s stock valued at $7,503,000 after purchasing an additional 106,200 shares during the last quarter. Piedmont Investment Advisors Inc. boosted its position in Corcept Therapeutics by 5.3% during the first quarter. Piedmont Investment Advisors Inc. now owns 26,196 shares of the biotechnology company’s stock valued at $308,000 after purchasing an additional 1,321 shares during the last quarter. Finally, Norges Bank acquired a new stake in Corcept Therapeutics during the fourth quarter valued at $9,423,000. 75.63% of the stock is owned by hedge funds and other institutional investors.
NASDAQ CORT traded up $1.54 during trading on Friday, hitting $12.50. 2,456,497 shares of the company traded hands, compared to its average volume of 539,572. Corcept Therapeutics Incorporated has a 12 month low of $9.14 and a 12 month high of $19.48. The business’s fifty day simple moving average is $10.83. The company has a market cap of $1.29 billion, a P/E ratio of 18.46 and a beta of 1.47.
A number of analysts recently issued reports on the company. Cantor Fitzgerald reissued a “hold” rating and set a $14.00 price objective on shares of Corcept Therapeutics in a research report on Wednesday, May 1st. Zacks Investment Research raised Corcept Therapeutics from a “sell” rating to a “hold” rating and set a $12.00 price objective for the company in a research report on Wednesday. ValuEngine raised Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. BidaskClub raised Corcept Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 14th. Finally, TheStreet lowered Corcept Therapeutics from a “b” rating to a “c+” rating in a report on Friday, May 10th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $12.00.
In other Corcept Therapeutics news, Director G Leonard Baker, Jr. sold 30,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $9.78, for a total transaction of $293,400.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 15.50% of the stock is owned by company insiders.
About Corcept Therapeutics
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Featured Article: What does a neutral rating on stocks mean?
Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.